Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561844 | 0.81 | PRKCA (0.38) | PRKCAPOLBGAANPSR1ALOX15 | |
| SCHEMBL17708339 | 0.79 | CYP4F2 (0.36) | POLBGAAALOX15LMNAHSD17B10 | |
| SCHEMBL28019636 | 0.79 | PRKCA (0.43) | PRKCAPOLBGAANPSR1ALDH1A1 | |
| SCHEMBL7089654 | 0.77 | PRKCA (0.42) | PRKCAPOLBGAANPSR1ALDH1A1 | |
| SCHEMBL13647509 | 0.77 | MAPK1 (0.47) | PRKCAPOLBGAANPSR1ALDH1A1 | |
| SCHEMBL8816807 | 0.77 | PRKCA (0.42) | PRKCAPOLBGAANPSR1LMNA | |
| SCHEMBL3517297 | 0.77 | PRKCA (0.42) | PRKCAPOLBGAANPSR1LMNA | |
| SCHEMBL9866275 | 0.77 | PRKCA (0.42) | PRKCAPOLBGAANPSR1ELANE | |
| SCHEMBL1557517 | 0.75 | KDM4E (0.33) | GAALMNAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL7222887 | 0.75 | PRKCA (0.41) | PRKCAPOLBGAANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565461-A2 | ANTIBACTERIAL SUBSTITUTED CYANOMETHYL(ENE)PIPERIDINOPHENYL OXAZOLIDINONES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Patel, Mahesh V. (IN) | 2005-08-24 | — | — | EP | claimed |
| WO-2004007489-A2 | ANTIBACTERIAL SUBSTITUTED CYANOMETHYL (ENE) PIPERIDINOPHENYL OXAZOLIDINONES, PROCESS OR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WOCKHARDT LIMITED (IN) | 2004-01-22 | — | — | WO | claimed |
| CN-110291068-A | The method for being used to prepare 2- pyridyl-ethyl group carboxamides derivatives | 拜耳农作物科学股份公司 | 2019-09-27 | — | — | CN | disclosed |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-07-03 | — | — | US | disclosed |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | AR, SHBG, BRCA1 | PRKCA 1839/4885POLB 40/4885GAA 4189/4885 |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | AR, FSHR, ESRRB | PRKCA 2378/4885POLB 46/4885GAA 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.